Julio Echegoyen, PhD
Ophthalmology · San Diego, CANPI 1770801540
Payments from drug & device makers
Across 891 payments — averaging $324.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$197K
- Sight Sciences, Inc.$47K
- Alcon$20K
- Glaukos Corporation$5K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$5K
- Ocular Therapeutix, Inc.$4K
- plus $10K from 25 others
What the payments were for
- Consulting fees$36,08851%
- Speaking & faculty fees$9,27813%
- Travel & lodging$5201%
- Food & beverage$25,08335%
- Education$1510%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 147 | $197,446 |
| Sight Sciences, Inc. | 32 | $47,383 |
| Alcon | 372 | $20,004 |
| Glaukos Corporation | 53 | $5,170 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 17 | $4,531 |
| Ocular Therapeutix, Inc. | 63 | $4,013 |
| Rxsight Inc | 9 | $2,937 |
| Ivantis, Inc | 30 | $1,337 |
| Carl Zeiss Meditec USA, Inc. | 8 | $945 |
| Harrow Eye, LLC | 23 | $775 |
| Biotissue Holdings Inc. | 15 | $742 |
| Bausch & Lomb Americas Inc. | 34 | $726 |
| Dompe US, Inc. | 8 | $391 |
| Novartis | 16 | $363 |
| AbbVie(2 entities) | 18 | $316 |
| Carl Zeiss Meditec, Inc. | 4 | $309 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $261 |
| Tarsus Pharmaceuticals, Inc. | 6 | $237 |
| Amgen(2 entities) | 4 | $193 |
| Sun Pharmaceutical Industries Inc. | 4 | $97 |
| Carl Zeiss Meditec Cataract Technology Inc. | 1 | $96 |
| Aerie Pharmaceuticals, Inc. | 4 | $72 |
| Shire North American Group Inc | 3 | $65 |
| Staar Surgical Company | 1 | $56 |
| Kala Pharmaceuticals, Inc. | 3 | $53 |
| Oyster Point Pharma, Inc. | 2 | $43 |
| Mallinckrodt Hospital Products Inc. | 2 | $42 |
| Optovue, Inc. | 1 | $40 |
| Thea Pharma Inc. | 1 | $23 |
| Eyevance Pharmaceuticals LLC | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Centurion$6,756
- ENVISTA TORIC$4,049
- DEXTENZA$3,466
- LenSx$3,143
- Unity$2,755
- Clareon$2,738
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$2,647
- TEARCARE SYSTEM$2,000
- NGENUITY$700
- Wavelight Refractive Suite$644
- KXL System$634
- ARTEVO 800$527
- Hydrus Microstent$517
- iDoseTR$400
- iStent Infinite$400
- AcrySof IQ VIVITY IOL$380
- CE-marked KXLA system$300
- ARGOS$274
- AcrySof$270
- Clareon PanOptix Pro$269
How this compares
$288,704 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 26 | $20,493 |
| XiidraLifitegrast | 21 | $18,604 |
| VyzultaLatanoprostene Bunod | 53 | $16,589 |
| LumiganBimatoprost | 33 | $12,375 |
| Prednisolone Acetate | 288 | $9,570 |
| MoxifloxacinMoxifloxacin Hcl | 237 | $5,946 |
| CombiganBrimonidine Tartrate/Timolol | 20 | $5,894 |
| Loteprednol Etabonate | 36 | $5,330 |
| ZioptanTafluprost/Pf | 18 | $4,613 |
| Cyclosporine | 20 | $4,602 |
| ProlensaBromfenac Sodium | 11 | $3,497 |
| RhopressaNetarsudil Mesylate | 11 | $3,365 |
| Difluprednate | 34 | $3,011 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 14 | $2,848 |
| Ketorolac Tromethamine | 195 | $2,652 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $316 | $38,76279 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $726 | $35,19374 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Prolensa | $4,531 | $8,82747 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $72 | $3,36511 claims |
| AlconSimbrinza | $20,004 | $2,84814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in San Diego
- William FreemanSan Diego$997K
- Eric NudlemanSan Diego$752K
- Robert WeinrebSan Diego$660K
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.